| . | All . | Former period* . | Latter period† . | . |
|---|---|---|---|---|
| . | (n = 203) . | (n = 79) . | (n = 124) . | P . |
| Tumour differentiation‡ | 0.015 | |||
| Well | 39 (19.2) | 20 (25.3) | 19 (15.3) | |
| Moderate | 116 (57.2) | 34 (43.0) | 82 (66.1) | |
| Poor | 46 (22.7) | 24 (30.4) | 22 (17.7) | |
| Others§ | 2 (0.9) | 1 (1.3) | 1 (0.8) | |
| pT category‡ | 0.002 | |||
| T1 | 32 (15.8) | 5 (6.3) | 27 (21.8) | |
| T2 | 111 (54.7) | 42 (43.0) | 69 (55.6) | |
| T3 | 48 (23.6) | 28 (35.4) | 20 (16.1) | |
| T4 | 12 (5.9) | 4 (5.1) | 8 (6.5) | |
| pN category‡ | 0.002 | |||
| N0 | 72 (35.5) | 18 (22.8) | 54 (43.5) | |
| N1 | 85 (41.9) | 35 (44.3) | 50 (37.1) | |
| N2 | 46 (22.6) | 26 (32.9) | 20 (13.7) | |
| pM category‡ | 0.015 | |||
| M0 | 183 (90.1) | 66 (83.5) | 117 (94.4) | |
| M1¶ | 20 (9.9) | 13 (32.9) | 7 (13.7) | |
| Lavage cytology | 0.051 | |||
| Negative | 189 (93.1) | 70 (88.6) | 119 (94.4) | |
| Positive | 14 (6.9) | 9 (11.4) | 5 (5.6) | |
| Residual tumour status‡ | <0.001 | |||
| R0 | 172 (84.7) | 56 (70.1) | 116 (93.5) | |
| R1 | 31 (15.3) | 23 (29.1) | 8 (6.5) |
| . | All . | Former period* . | Latter period† . | . |
|---|---|---|---|---|
| . | (n = 203) . | (n = 79) . | (n = 124) . | P . |
| Tumour differentiation‡ | 0.015 | |||
| Well | 39 (19.2) | 20 (25.3) | 19 (15.3) | |
| Moderate | 116 (57.2) | 34 (43.0) | 82 (66.1) | |
| Poor | 46 (22.7) | 24 (30.4) | 22 (17.7) | |
| Others§ | 2 (0.9) | 1 (1.3) | 1 (0.8) | |
| pT category‡ | 0.002 | |||
| T1 | 32 (15.8) | 5 (6.3) | 27 (21.8) | |
| T2 | 111 (54.7) | 42 (43.0) | 69 (55.6) | |
| T3 | 48 (23.6) | 28 (35.4) | 20 (16.1) | |
| T4 | 12 (5.9) | 4 (5.1) | 8 (6.5) | |
| pN category‡ | 0.002 | |||
| N0 | 72 (35.5) | 18 (22.8) | 54 (43.5) | |
| N1 | 85 (41.9) | 35 (44.3) | 50 (37.1) | |
| N2 | 46 (22.6) | 26 (32.9) | 20 (13.7) | |
| pM category‡ | 0.015 | |||
| M0 | 183 (90.1) | 66 (83.5) | 117 (94.4) | |
| M1¶ | 20 (9.9) | 13 (32.9) | 7 (13.7) | |
| Lavage cytology | 0.051 | |||
| Negative | 189 (93.1) | 70 (88.6) | 119 (94.4) | |
| Positive | 14 (6.9) | 9 (11.4) | 5 (5.6) | |
| Residual tumour status‡ | <0.001 | |||
| R0 | 172 (84.7) | 56 (70.1) | 116 (93.5) | |
| R1 | 31 (15.3) | 23 (29.1) | 8 (6.5) |
Values are n (%). *From 2010 to 2015. †From 2016 to 2021. ‡According to the AJCC TNM staging system, 8th edition23. §One with adenosquamous carcinoma and the other with acinar cell carcinoma. pT, pathological T; pN, pathological N; pM, pathological M. ¶The sites of metastasis were the para-aortic lymph nodes in 16 patients, the liver in three patients, and a para-aortic lymph node and peritoneum in a patient; R0, no residual tumour; R1, microscopic residual tumour.
| . | All . | Former period* . | Latter period† . | . |
|---|---|---|---|---|
| . | (n = 203) . | (n = 79) . | (n = 124) . | P . |
| Tumour differentiation‡ | 0.015 | |||
| Well | 39 (19.2) | 20 (25.3) | 19 (15.3) | |
| Moderate | 116 (57.2) | 34 (43.0) | 82 (66.1) | |
| Poor | 46 (22.7) | 24 (30.4) | 22 (17.7) | |
| Others§ | 2 (0.9) | 1 (1.3) | 1 (0.8) | |
| pT category‡ | 0.002 | |||
| T1 | 32 (15.8) | 5 (6.3) | 27 (21.8) | |
| T2 | 111 (54.7) | 42 (43.0) | 69 (55.6) | |
| T3 | 48 (23.6) | 28 (35.4) | 20 (16.1) | |
| T4 | 12 (5.9) | 4 (5.1) | 8 (6.5) | |
| pN category‡ | 0.002 | |||
| N0 | 72 (35.5) | 18 (22.8) | 54 (43.5) | |
| N1 | 85 (41.9) | 35 (44.3) | 50 (37.1) | |
| N2 | 46 (22.6) | 26 (32.9) | 20 (13.7) | |
| pM category‡ | 0.015 | |||
| M0 | 183 (90.1) | 66 (83.5) | 117 (94.4) | |
| M1¶ | 20 (9.9) | 13 (32.9) | 7 (13.7) | |
| Lavage cytology | 0.051 | |||
| Negative | 189 (93.1) | 70 (88.6) | 119 (94.4) | |
| Positive | 14 (6.9) | 9 (11.4) | 5 (5.6) | |
| Residual tumour status‡ | <0.001 | |||
| R0 | 172 (84.7) | 56 (70.1) | 116 (93.5) | |
| R1 | 31 (15.3) | 23 (29.1) | 8 (6.5) |
| . | All . | Former period* . | Latter period† . | . |
|---|---|---|---|---|
| . | (n = 203) . | (n = 79) . | (n = 124) . | P . |
| Tumour differentiation‡ | 0.015 | |||
| Well | 39 (19.2) | 20 (25.3) | 19 (15.3) | |
| Moderate | 116 (57.2) | 34 (43.0) | 82 (66.1) | |
| Poor | 46 (22.7) | 24 (30.4) | 22 (17.7) | |
| Others§ | 2 (0.9) | 1 (1.3) | 1 (0.8) | |
| pT category‡ | 0.002 | |||
| T1 | 32 (15.8) | 5 (6.3) | 27 (21.8) | |
| T2 | 111 (54.7) | 42 (43.0) | 69 (55.6) | |
| T3 | 48 (23.6) | 28 (35.4) | 20 (16.1) | |
| T4 | 12 (5.9) | 4 (5.1) | 8 (6.5) | |
| pN category‡ | 0.002 | |||
| N0 | 72 (35.5) | 18 (22.8) | 54 (43.5) | |
| N1 | 85 (41.9) | 35 (44.3) | 50 (37.1) | |
| N2 | 46 (22.6) | 26 (32.9) | 20 (13.7) | |
| pM category‡ | 0.015 | |||
| M0 | 183 (90.1) | 66 (83.5) | 117 (94.4) | |
| M1¶ | 20 (9.9) | 13 (32.9) | 7 (13.7) | |
| Lavage cytology | 0.051 | |||
| Negative | 189 (93.1) | 70 (88.6) | 119 (94.4) | |
| Positive | 14 (6.9) | 9 (11.4) | 5 (5.6) | |
| Residual tumour status‡ | <0.001 | |||
| R0 | 172 (84.7) | 56 (70.1) | 116 (93.5) | |
| R1 | 31 (15.3) | 23 (29.1) | 8 (6.5) |
Values are n (%). *From 2010 to 2015. †From 2016 to 2021. ‡According to the AJCC TNM staging system, 8th edition23. §One with adenosquamous carcinoma and the other with acinar cell carcinoma. pT, pathological T; pN, pathological N; pM, pathological M. ¶The sites of metastasis were the para-aortic lymph nodes in 16 patients, the liver in three patients, and a para-aortic lymph node and peritoneum in a patient; R0, no residual tumour; R1, microscopic residual tumour.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
